Risk of endometrial cancer in women treated with ovary-stimulating drugs for subfertility.

CONCLUSIONS: The synthesis of the currently available evidence does not allow us to draw robust conclusions, due to the very low quality of evidence. It seems that exposure to clomiphene citrate as an ovary-stimulating drug in subfertile women is associated with increased risk of endometrial cancer, especially at doses greater than 2000 mg and high (more than 7) number of cycles. This may largely be due to underlying risk factors in women who need treatment with clomiphene citrate, such as polycystic ovary syndrome, rather than exposure to the drug itself. The evidence regarding exposure to gonadotropins was inconclusive.
PMID: 28349511 [PubMed - as supplied by publisher]

Source: Cochrane Database of Systematic Reviews - March 25, 2017 Category: Journals (General) Authors: Skalkidou A, Sergentanis TN, Gialamas SP, Georgakis MK, Psaltopoulou T, Trivella M, Siristatidis CS, Evangelou E, Petridou E Tags: Cochrane Database Syst Rev Source Type: research